Amanda L. Fyles

FDA investigator

Appears on 5 documents from 2017 to 2019, mostly at sites in California. Most often cites testing and release for distribution (21 CFR 211.165).

5
Documents on file
8.6
Observations per 483
2017
First seen
2019
Most recent

What they cite most

From 43 observations

Activity by year

2017: 2, 2018: 1, 2019: 2

Where

California 5

Is Amanda L. Fyles coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

5 documents, newest first
FirmOpen
483 PYRAMID Laboratories, Inc.Apr 11, 2019 · Costa Mesa, California
483 Teva Parenteral Medicines, Inc.Jan 18, 2019 · Irvine, California
483 B. Braun US Pharmaceutical Manufacturing LLCJun 29, 2018 · Irvine, California
483 Alliance Medical Products, Inc. (dba Siegfried Irvine)May 26, 2017 · Irvine, California
483 Amphastar Pharmaceuticals, IncMar 31, 2017 · Rancho Cucamonga, California

About this profile

What does Amanda L. Fyles inspect?

Amanda L. Fyles appears on 5 documents on file covering 5 sites, mostly in California.

What do they cite most often?

21 CFR 211.165 (testing and release for distribution), followed by 21 CFR 820.30 and 21 CFR 211.100.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Amanda L. Fyles is dated Apr 11, 2019.